The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies.
UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing ...
New findings explore the adalimumab biosimilar landscape, focusing on formulation, devices, and patient support programs that ...
New clinical data confirms Bmab 1200, a biosimilar to ustekinumab, offers equivalent efficacy and safety for treating ...
October 2025 marks a transformative period for biosimilars, with new FDA guidelines accelerating approvals and promising significant cost savings for health care.
A recent study reveals global regulatory inconsistencies in biosimilars, urging convergence to enhance access and savings for patients and health care systems.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback